Nevro Corp. (NYSE:NVRO) General Counsel Purchases $100,125.00 in Stock

Nevro Corp. (NYSE:NVROGet Rating) General Counsel Kashif Rashid acquired 2,250 shares of the firm’s stock in a transaction that occurred on Monday, May 9th. The shares were bought at an average price of $44.50 per share, with a total value of $100,125.00. Following the acquisition, the general counsel now directly owns 53,526 shares of the company’s stock, valued at approximately $2,381,907. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Kashif Rashid also recently made the following trade(s):

  • On Friday, March 11th, Kashif Rashid bought 1,500 shares of Nevro stock. The shares were acquired at an average price of $64.04 per share, with a total value of $96,060.00.

Nevro stock opened at $44.56 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 6.97 and a quick ratio of 5.32. The company has a market capitalization of $1.57 billion, a P/E ratio of -11.43 and a beta of 1.07. The stock has a fifty day simple moving average of $67.88. Nevro Corp. has a twelve month low of $42.97 and a twelve month high of $182.45.

Nevro (NYSE:NVROGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The medical equipment provider reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.13. The business had revenue of $87.40 million during the quarter, compared to the consensus estimate of $86.19 million. Nevro had a negative net margin of 35.25% and a negative return on equity of 38.02%. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.85) earnings per share. As a group, analysts predict that Nevro Corp. will post -2.86 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Nevro by 3.5% during the fourth quarter. BlackRock Inc. now owns 4,150,231 shares of the medical equipment provider’s stock valued at $336,460,000 after acquiring an additional 141,160 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Nevro by 15.6% during the fourth quarter. Capital Research Global Investors now owns 1,582,704 shares of the medical equipment provider’s stock valued at $128,310,000 after acquiring an additional 213,670 shares during the last quarter. State Street Corp raised its stake in shares of Nevro by 2.7% during the fourth quarter. State Street Corp now owns 774,549 shares of the medical equipment provider’s stock valued at $62,793,000 after acquiring an additional 20,017 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Nevro by 47.1% during the third quarter. Wellington Management Group LLP now owns 666,273 shares of the medical equipment provider’s stock valued at $77,542,000 after acquiring an additional 213,187 shares during the last quarter. Finally, Brown Advisory Inc. raised its stake in Nevro by 16.7% in the first quarter. Brown Advisory Inc. now owns 611,745 shares of the medical equipment provider’s stock worth $44,273,000 after buying an additional 87,633 shares in the last quarter.

A number of research analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Nevro in a research report on Tuesday, April 5th. They set an “underperform” rating and a $64.00 price target for the company. StockNews.com upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research report on Tuesday. Bank of America assumed coverage on shares of Nevro in a research report on Wednesday, March 2nd. They set an “underperform” rating for the company. Canaccord Genuity Group reduced their price target on shares of Nevro from $97.00 to $72.00 and set a “hold” rating for the company in a research report on Friday, February 25th. Finally, Citigroup upgraded shares of Nevro from a “neutral” rating to a “buy” rating and set a $78.00 target price for the company in a research report on Thursday, May 5th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $100.54.

About Nevro (Get Rating)

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.

Featured Articles

Insider Buying and Selling by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.